Verdiva Halts Oral GLP-1 Study Citing Market Shifts | Retatrutide News

Verdiva ended its mid-stage trial of an oral GLP-1 agonist due to market evolution. This decision reflects the competitive landscape affecting GLP-1 res...
Market News · October 15, 2026